Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention
- PMID: 25662743
- DOI: 10.1111/head.12505_2
Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention
Abstract
Migraine is a common disabling primary headache disorder that affects an estimated 36 million Americans. Migraine headaches often occur over many years or over an individual's lifetime. By definition, episodic migraine is characterized by headaches that occur on fewer than 15 days per month. According to the recent International Classification of Headache Disorders (third revision) beta diagnostic criteria, chronic migraine is defined as "headaches on at least 15 days per month for at least 3 months, with the features of migraine on at least 8 days per month." However, diagnostic criteria distinguishing episodic from chronic migraine continue to evolve. Persons with episodic migraine can remit, not change, or progress to high-frequency episodic or chronic migraine over time. Chronic migraine is associated with a substantially greater personal and societal burden, more frequent comorbidities, and possibly with persistent and progressive brain abnormalities. Many patients are poorly responsive to, or noncompliant with, conventional preventive therapies. The primary goals of migraine treatment include relieving pain, restoring function, and reducing headache frequency; an additional goal may be preventing progression to chronic migraine. Although all migraineurs require abortive treatment, and all patients with chronic migraine require preventive treatment, there are no definitive guidelines delineating which persons with episodic migraine would benefit from preventive therapy. Five US Food and Drug Association strategies are approved for preventing episodic migraine, but only injections with onabotulinumtoxinA are approved for preventing chronic migraine. Identifying persons who require migraine prophylaxis and selecting and initiating the most appropriate treatment strategy may prevent progression from episodic to chronic migraine and alleviate the pain and suffering associated with frequent migraine.
Keywords: chronic migraine; diagnosis; episodic migraine; iontophoretic transdermal system; onabotulinumtoxinA injection; treatment.
© 2015 American Headache Society.
Similar articles
-
Development of onabotulinumtoxinA for chronic migraine.Ann N Y Acad Sci. 2014 Nov;1329:67-80. doi: 10.1111/nyas.12488. Epub 2014 Aug 18. Ann N Y Acad Sci. 2014. PMID: 25399521 Review.
-
Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.Headache. 2012 Sep;52(8):1219-25. doi: 10.1111/j.1526-4610.2012.02164.x. Epub 2012 May 18. Headache. 2012. PMID: 22607530 Clinical Trial.
-
Persistent frequent nausea is associated with progression to chronic migraine: AMPP study results.Headache. 2015 Jan;55(1):76-87. doi: 10.1111/head.12450. Epub 2014 Sep 24. Headache. 2015. PMID: 25250833
-
Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: a meta-analysis.JAMA. 2012 Apr 25;307(16):1736-45. doi: 10.1001/jama.2012.505. JAMA. 2012. PMID: 22535858
-
A Narrative Review of Evidence-Based Preventive Options for Chronic Migraine.Curr Pain Headache Rep. 2015 Oct;19(10):49. doi: 10.1007/s11916-015-0521-0. Curr Pain Headache Rep. 2015. PMID: 26286071 Review.
Cited by
-
Preventive treatment patterns in the adult migraine population: an observational UK study over 7 years.BMC Prim Care. 2024 Jan 24;25(1):34. doi: 10.1186/s12875-023-02242-y. BMC Prim Care. 2024. PMID: 38262999 Free PMC article.
-
Effectiveness of combining greater occipital nerve block and pulsed radiofrequency treatment in patients with chronic migraine: a double-blind, randomized controlled trial.Head Face Med. 2024 Sep 11;20(1):48. doi: 10.1186/s13005-024-00449-7. Head Face Med. 2024. PMID: 39256847 Free PMC article. Clinical Trial.
-
Migraine management: Non-pharmacological points for patients and health care professionals.Open Med (Wars). 2022 Nov 23;17(1):1869-1882. doi: 10.1515/med-2022-0598. eCollection 2022. Open Med (Wars). 2022. PMID: 36475060 Free PMC article. Review.
-
Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience.J Headache Pain. 2020 Jun 9;21(1):69. doi: 10.1186/s10194-020-01143-0. J Headache Pain. 2020. PMID: 32517693 Free PMC article. Clinical Trial.
-
Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems.Nat Rev Drug Discov. 2023 May;22(5):387-409. doi: 10.1038/s41573-023-00670-0. Epub 2023 Mar 27. Nat Rev Drug Discov. 2023. PMID: 36973491 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical